GSK (LSE:GSK) has agreed to acquire a trispecific T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences, a privately held biotechnology company.
The deal carries a total potential value of up to $750 million, comprising an upfront fee for full global rights plus success-based development and commercial milestone payments.
The asset binds to T cells while targeting two validated tumour-associated antigens, an approach designed to improve on existing TCEs, which have shown strong efficacy in multiple myeloma but difficult tolerability profiles.
GSK expects the programme to enter phase I trials in 2027.
"Today's deal secures a promising T cell engager and advances GSK's leadership goals in blood cancer," said Hesham Abdullah, senior vice president and global head of oncology R&D at GSK.
The agreement extends an existing relationship between the two companies: GSK previously acquired CMG1A46, a Chimagen dual CD19/CD20-targeted TCE now in phase I trials for B-cell malignancies and autoimmune disorders.
Multiple myeloma is the third most common blood cancer globally, with around 180,000 new cases diagnosed each year, and remains incurable despite being generally treatable.
External commercial forecasts cited by GSK put the US TCE market for multiple myeloma at more than $10 billion by 2032.
The agreement is subject to customary closing conditions.
News Intelligence what this means for the company
GSK is acquiring a trispecific T cell-engager for multiple myeloma from Chimagen for up to $750 million—an upfront payment plus development and commercial milestones. The asset targets two tumor antigens and is designed to address tolerability issues seen in existing T cell-engagers; GSK expects phase I entry in 2027. This extends an existing relationship: GSK previously acquired CMG1A46, a Chimagen dual-targeted TCE now in phase I for B-cell malignancies, signaling confidence in Chimagen's platform and GSK's commitment to blood cancer oncology.
The deal adds a potentially high-value late-stage oncology asset to GSK's pipeline in a market GSK forecasts at over $10 billion in the US by 2032, reinforcing its oncology strategy. At $750 million total value against GSK's $40+ billion annual revenue base, the upfront and near-term milestone exposure is modest, with most value contingent on clinical and commercial success.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
